Related Experiment Videos
Current concepts and controversy in chronic inflammatory demyelinating polyneuropathy
David S Saperstein1, Richard J Barohn
1Department of Neurology, The University of Kansas Medical Center, 1005B Wescoe, 3901 Rainbow Boulevard, Kansas City, KS 66160, USA. dsaperstein@kumc.edu
Current Neurology and Neuroscience Reports
|January 1, 2003
Summary
Chronic inflammatory demyelinating polyneuropathy (CIDP) is a treatable autoimmune nerve disorder. Early diagnosis through clinical, lab, and electrodiagnostic tests is crucial for effective management of this common neuropathy.
Area of Science:
- Neurology
- Immunology
- Clinical Neuroscience
Background:
- Chronic inflammatory demyelinating polyneuropathy (CIDP) is an acquired, immune-mediated demyelinating neuropathy.
- It is the most common treatable acquired polyneuropathy.
- Represents a significant number of initially undiagnosed neuropathy patients.
Purpose of the Study:
- To review the common clinical, laboratory, and electrodiagnostic features of CIDP.
- To discuss current areas of uncertainty in CIDP diagnosis and management.
Main Methods:
- Review of existing literature on CIDP.
- Synthesis of clinical, laboratory, and electrodiagnostic findings.
- Discussion of diagnostic challenges and uncertainties.
Main Results:
- CIDP presents with characteristic clinical, laboratory, and electrodiagnostic findings.
- Despite being treatable, a significant number of CIDP cases are initially undiagnosed.
- Key areas of diagnostic uncertainty remain.
Conclusions:
- Early recognition of CIDP is essential due to its treatable nature.
- Comprehensive evaluation including clinical assessment, laboratory tests, and electrodiagnostics aids diagnosis.
- Further research is needed to address current uncertainties in CIDP management.